BioCryst presents real-world data at AAAAI annual meeting showing ORLADEYO reduces HAE attack rates for 18 months.

BioCryst presents real-world data at AAAAI annual meeting, showing ORLADEYO (berotralstat) reduces HAE attack rates rapidly, substantially, and sustainably for 18 months, regardless of disease severity, prior prophylaxis, or C1-inhibitor level/function. The data are presented in five posters at the 2024 AAAAI meeting in Washington, D.C.